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Desensitization of 5-HT1A receptors could be involved in the
long-term therapeutic effect of anxiolytic and antidepressant
drugs. Pretreatment of rats with the 5-HT2A/2C agonist DOI
induces an attenuation of hypothalamic 5-HT1A receptor–Gz-
protein signaling, measured as the ACTH and oxytocin re-
sponses to an injection of the 5-HT1A agonist 8-OH-DPAT. We
characterized this functional heterologous desensitization of
5-HT1A receptors in rats and examined some of the mecha-
nisms that are involved. A time course experiment revealed that
DOI produces a delayed and reversible reduction of the ACTH
and oxytocin responses to an 8-OH-DPAT challenge. The max-
imal desensitization occurred at 2 hr, and it disappeared 24 hr
after DOI injection. The desensitization was dose-dependent,
and it shifted the oxytocin and ACTH dose–response curves of
8-OH-DPAT to the right (increased ED50) with no change in their
maximal responses (Emax ). The 5-HT2A receptor antagonist
MDL 100,907 prevented the DOI-induced desensitization, indi-
cating that 5-HT2A receptors mediate the effect of DOI. Analysis
of the components of the 5-HT1A receptor–Gz-protein signaling
system showed that DOI did not alter the level of membrane-
associated Gz-proteins in the hypothalamus. Additionally, DOI
did not alter the binding of [3H]8-OH-DPAT or the inhibition by
GTPS of [3H]8-OH-DPAT binding in the hypothalamus. In
conclusion, the activation of 5-HT2A receptors induces a tran-
sient functional desensitization of 5-HT1A receptor signaling in
the hypothalamus, which may occur distal to the 5-HT1A
receptor–Gz-protein interface.
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Among the seven families of serotonin receptors, 5-HT1A and
5-HT2A receptors have an important role in mood disorders
(Stockmeier et al., 1997; Staley et al., 1998; Olivier et al., 1999;
Sargent et al., 2000). Selective serotonin reuptake inhibitors
(SSRIs) produce a desensitization of 5-HT1A receptors (Li et al.,
1996; Berlin et al., 1998; Raap et al., 1999; Bosker et al., 2001) and
alter the functioning of 5-HT2A receptors (Tilakaratne et al.,
1995; Bonson et al., 1996; Raap and Van de Kar, 1999). Desen-
sitization of 5-HT1A receptors could contribute to the therapeutic
effects of SSRIs. Because chronic treatment with SSRIs results in
long-term elevation in the levels of 5-HT in the synapse, SSRIs
could produce a heterologous desensitization of 5-HT1A recep-
tors by the activation of other 5-HT receptors.
5-HT1A receptors and 5-HT2 receptors interact via their sig-
naling proteins (Katada et al., 1985; Berg et al., 1998; Tournois et
al., 1998; Evans et al., 2001). In Chinese hamster ovary (CHO)
cells stably expressing the human 5-HT1A receptors and 5-HT2C
receptors, the activation of 5-HT2C receptors induces a heterol-
ogous desensitization of 5-HT1A receptors via protein kinase C
and a cyclooxygenase-dependent metabolite of arachidonic acid
(Evans et al., 2001). 5-HT2A receptors are coupled also via Gq/11
proteins to phospholipase C and phospholipase A2 signaling path-
ways (Garcia and Kim, 1997; Grotewiel and Sanders-Bush, 1999).
Thus 5-HT2A receptors could cross-talk to 5-HT1A receptors to
produce a heterologous desensitization of 5-HT1A receptors.
Functional interactions between 5-HT1A receptors and
5-HT2A/2C receptors have been demonstrated in behavioral stud-
ies. These studies either examined the effect of 5-HT1A receptor
activation on 5-HT2A/2C receptor-mediated behaviors (Darmani
et al., 1990; Krebs-Thomson and Geyer, 1998) or determined the
impact of 5-HT2A/2C receptor desensitization on the behavioral
and temperature responses to 5-HT1A receptor activation (Hen-
sler and Truett, 1998). To our knowledge, only one group has
examined the impact of 5-HT2A/2C receptor activation on the
reproductive behavioral response to 8-OH-DPAT (Maswood and
Uphouse, 1997).
5-HT1A receptors labeled with [
3H]8-OH-DPAT and
5-HT2A/2C receptors labeled with [I
125]DOI are found in the
hypothalamic paraventricular nucleus (PVN) (Appel et al., 1990;
Li et al., 1997), where oxytocin and corticotropin-releasing factor
(CRF) cells are located (Sawchenko and Swanson, 1985). Evi-
dence indicates that 8-OH-DPAT-induced release of oxytocin
and adrenocorticotropic hormone (ACTH) is mediated by
5-HT1A receptor–Gz-protein signaling in the hypothalamic para-
ventricular nucleus (Serres et al., 2000). Activation of hypotha-
lamic 5-HT2A receptors also mediates oxytocin and ACTH re-
lease (Bagdy 1996; Van de Kar et al., 2001). Thus the 8-OH-
DPAT-induced increase in the plasma levels of ACTH and
oxytocin is a useful index of the sensitivity of hypothalamic
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5-HT1A receptors and can be used to examine the interaction
between 5-HT2A and 5-HT1A receptors in the hypothalamus.
The present study is the first in vivo characterization of a
functional heterologous desensitization of 5-HT1A receptors af-
ter 5-HT2A receptor activation with DOI. In addition, the hypo-
thalamic levels of membrane-associated Gz-protein and the cou-
pling of hypothalamic 5-HT1A receptors to G-proteins were




Male Sprague Dawley rats (225–275 gm) were purchased from Harlan
Sprague Dawley (Indianapolis, IN). The rats were housed two per cage
in a temperature-, humidity-, and light-controlled room (12 hr light /dark
cycle, lights on from 7:00 A.M. to 7:00 P.M.). Food and water were
available ad libitum. All procedures were conducted in accordance with
National Institutes of Health Guide for the Care and Use of Laboratory
Animals as approved by Loyola University Institutional Animal Care and
Use Committee.
Drugs
8-Hydroxy-2-(di-n-propylamino) tetralin hydrobromide ([ 3H]8-
OH-DPAT) and ()-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
HCl (DOI) were purchased from Research Biochemicals (Natick,
M A). ()--(2,3-Dimethox y phenyl)-1-(2-fluorophenylethyl-4-
piperidinemethanol (MDL 100,907) was donated generously by
Hoechst Marion Roussel Research Institute (Cincinnati, OH). 8-OH-
DPAT was dissolved in 0.9% saline at four concentrations (0.03, 0.05,
0.1, and 0.5 mg/ml). DOI was dissolved in 0.9% saline at three concen-
trations (0.5, 2.5, and 5 mg/ml). MDL 100,907 was dissolved in a minimal
volume of 0.01N HCl and diluted with saline to the final concentration of
0.01 mg/ml. All solutions were made fresh before injections and injected
at a volume of 1 ml/kg.
Experimental protocols
After their arrival, the rats were housed two per cage for at least 1 week,
followed by 4 d of handling. On the day of the experiments the rats were
assigned randomly to different experimental groups (n  8 per group) to
receive drug treatments. Cage mates were assigned to the same treat-
ment group. After receiving different drug treatments, the rats were
decapitated. The trunk blood was collected in centrifuge tubes contain-
ing a 0.5 ml solution of 0.3 M EDTA, pH 7.4. After centrifugation the
plasma was stored at 70°C for radioimmunoassays of plasma hormone
concentrations. The hypothalamus was dissected, immediately frozen in
liquid nitrogen, and later stored at 70°C for immunoblot analysis and
receptor binding assays.
Time course of the effect of DOI on hormone responses to an 8-OH-
DPAT challenge. The 5-HT2A/2C receptor agonist DOI (2.5 mg/kg, i.p.)
or saline was administered to rats. At different time points after DOI
injection (1, 2, 4, 24 hr) the rats were challenged with the 5-HT1A agonist
8-OH-DPAT (0.05 mg/kg, s.c.) or saline. Then 15 min after the 8-OH-
DPAT injection the rats were decapitated.
Effect of pretreatment with increasing doses of DOI on hormone responses
to an 8-OH-DPAT challenge. Rats were injected with increasing doses of
DOI (0.5, 2.5 and 5 mg/kg, i.p.) or saline. At 2 hr later the rats were
challenged with 8-OH-DPAT (0.05 mg/kg, s.c.) or saline. Then 15 min
after the 8-OH-DPAT challenge the rats were decapitated.
Dose–response to an 8-OH-DPAT challenge in rats pretreated with DOI.
Rats were injected with DOI (2.5 mg/kg, i.p.) or saline. At 2 hr later the
rats were challenged with saline or increasing doses of 8-OH-DPAT
(0.03, 0.05, 0.1, 0.5 mg/kg, s.c.). Then 15 min after the 8-OH-DPAT
challenge the rats were decapitated.
Pretreatment with the 5-HT2A antagonist MDL 100,907. Rats first re-
ceived an injection of vehicle or the 5-HT2A antagonist MDL 100,907
(0.01 mg/kg, s.c.). At 15 min after this injection the rats received an
injection of DOI (2.5 mg/kg, i.p.) or saline. Then 2 hr after the DOI
injection the rats were challenged with 8-OH-DPAT (0.05 mg/kg, s.c.) or
saline. The rats were decapitated 15 min after the 8-OH-DPAT
challenge.
Radioimmunoassay
Plasma oxytocin and ACTH were determined by radioimmunoassays as
described previously in detail (Li et al., 1993, 1997).
Immunoblot analysis of Gz-proteins
Tissue preparation. All procedures were conducted at 4°C. Briefly, the
hypothalamic tissues were homogenized in 0.4 ml of 50 mM Tris buffer, pH
7.4, containing 150 mM NaCl, 10% sucrose, and 0.5 mM phenylmethane-
sulfonyl fluoride (PMSF) and additional protease inhibitors purchased as a
cocktail [containing 4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatin A,
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane, bestatin, leupep-
tin, and aprotinin] from Sigma (1.5 l /30 mg tissue; St. Louis, MO). After
centrifugation at 20,000  g for 60 min the pellets were collected and
resuspended by sonication in a 20 mM Tris buffer, pH 8 [containing (in mM)
1 EDTA, 100 NaCl, 1 dithiothreitol, and 1% sodium cholate] plus the
protease inhibitory cocktail (1.5 l cocktail /30 mg tissue) in a ratio of 3 l
buffer/mg tissue. The resuspended pellets were incubated while shaking for
1 hr and then centrifuged at 100,000  g for 60 min. The supernatant was
collected for the immunoblot analysis of membrane-bound Gz-protein
levels. The protein concentration was measured with a bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL).
Quantification of Gz-protein. Immunoblot analysis of membrane-
associated Gz-proteins has been described previously in detail (Raap et
al., 1999; Serres et al., 2000). Briefly, the solubilized proteins (2 g/ lane)
were resolved by SDS-PAGE and then transferred electrophoretically to
nitrocellulose membranes. After incubation with a blocking buffer (PBS
containing 0.2% casein and 0.1% Tween 20), the nitrocellulose mem-
branes were probed overnight at 4°C with polyclonal antisera for Gz
(I-20, 1:6000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). Then
the membranes were incubated with a secondary antibody (goat anti-
rabbit serum, 1:25,000 dilution for 1 hr; Cappell, Organon Teknika,
Durham, NC), followed by an incubation with rabbit peroxidase anti-
peroxidase (1:5000 dilution for 1 hr; Cappell, Organon Teknika). Finally,
the membranes were incubated with the ECL chemiluminescence sub-
strate solution (Amersham, Arlington Heights, IL) and then exposed to
Kodak x-ray film. Films were analyzed densitometrically with the Scion
Image program (Frederick, MD). The data for each sample were the
means of three replications and were calculated as integrated optical
densities (IOD)/g protein. The percentile changes of the mean IOD/g
protein values of each sample were calculated with respect to the average
of IOD/g protein values of saline-treated samples.
[3H]8-OH-DPAT binding
All procedures were performed on ice. The hypothalamic tissues were
homogenized quickly in 2 ml Tris buffer (50 mM), pH 7.7, using a
Polytron, and were centrifuged at 35,000  g for 10 min. The pellets were
resuspended with 2 ml of 50 mM Tris buffer, and the procedure was
repeated four times. Then the samples were diluted to a final concentra-
tion of 20 mg of tissue per milliliter for the receptor binding assay.
[ 3H]8-OH-DPAT binding (specific activity, 124.9 mCi/ml, 0.8 nM) was
performed in 1 ml of 50 mM Tris buffer, pH 7.7, containing 0.5 mM
EDTA, 10 mM MgSO4, 0.8 nM [
3H]8-OH-DPAT, 2 mg hypothalamic
tissue, and different concentrations of GTPS (from 10 9 to 10 5 M).
The specificity of [ 3H]8-OH-DPAT binding to 5-HT1A receptors was
defined in the presence of 1 M WAY100635. The ability of GTPS at
both IC50 (0.02 M) and Emax (1 M) concentrations to inhibit [
3H]8-
OH-DPAT labeling of 5-HT1A receptors was examined in hypothalamic
homogenates obtained from saline- and DOI-treated (2.5 mg/kg, i.p.)
rats. The protein concentration was measured with a BCA protein assay
kit (Pierce). 5-HT1A receptor binding was expressed as femtomoles per
milligram of protein.
Statistical analyses
The data are presented as group means (n  8) and the SEM. Except for
immunoblot data, all other data were analyzed by two-way or three-way
ANOVA. Group means were compared by a Newman–Keuls multiple
range test (Steel and Torrie, 1960). The immunoblot data were analyzed
by a Student’s t test. A computer program (GBSTAT, Silver Spring, MD)
was used for all of the statistical analyses.
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RESULTS
Time course of the effect of DOI on hormone
responses to a challenge with a 5-HT1A agonist
The 5-HT2A/2C receptor agonist DOI (2.5 mg/kg, i.p.) was in-
jected at different time points (1, 2, 4, 24 hr) before 8-OH-DPAT
challenge. DOI alone did not alter plasma oxytocin and ACTH
levels significantly at these time points. 8-OH-DPAT significantly
increased the plasma levels of oxytocin and ACTH by 731 and
930%, respectively. The time course effects of DOI on oxytocin
(Fig. 1A) and ACTH (Fig. 1B) showed a delayed onset and
reversible inhibition, by DOI, of the hormone responses to the
subsequent challenge with 8-OH-DPAT. For oxytocin the three-
way ANOVA indicated no significant main effects of time
(F(3,107)  0.04; p  0.1) but a significant main effect of DOI
(F(1,107)  9.96; p  0.01) and 8-OH-DPAT (F(1,107)  270.51; p 
0.01). The interaction between time and DOI was not significant.
However, there was a significant interaction between DOI and
8-OH-DPAT (F(1,107)  10.55; p  0.01). For ACTH the three-
way ANOVA indicated that there was a significant main effect of
8-OH-DPAT (F(1,106)  319.56; p  0.01). The main effect of time
(F(3,106)  2.45; p  0.05) and the main effect of DOI (F(1,106) 
3.23; p  0.05) were not significant. However, both the interac-
tions between time and DOI (F(3,106)  4.75; p  0.05) and
between DOI and 8-OH-DPAT (F(1,106)  10.48; p  0.05) were
significant. The Newman–Keuls test indicated that DOI signifi-
cantly decreased both plasma oxytocin and ACTH responses to
the 8-OH-DPAT challenge at 2 and 4 hr, with a maximal effect at
2 hr post-DOI administration (47% reduction for oxytocin; 51%
reduction for ACTH) (Fig. 1). At 1 hr after treatment with DOI
there was no inhibition of the effect of 8-OH-DPAT on either
ACTH or oxytocin levels (Fig. 1). These observations indicate
that activation of 5-HT2A/2C receptors produces a transient and
delayed onset attenuation of 5-HT1A receptor-mediated secretion
of oxytocin and ACTH.
Effect of pretreatment with increasing doses of DOI on
hormone responses to 8-OH-DPAT
DOI was administered at three doses: 0.5, 2.5, and 5 mg/kg
intraperitoneally, respectively. Basal plasma levels of oxytocin
and ACTH in saline-challenged rats were not altered significantly
by DOI at these doses. However, DOI inhibited the oxytocin (Fig.
2A) response to 8-OH-DPAT challenge in a dose-dependent
manner. For plasma oxytocin the two-way ANOVA indicated a
significant main effect of both DOI (F(3,55)  2.92; p  0.05) and
8-OH-DPAT (F(1,55)  71.08; p  0.01). There was a significant
interaction between DOI and 8-OH-DPAT (F(3,55)  3.08; p 
0.05). The Newman–Keuls test indicated that DOI significantly
reduced the effect of 8-OH-DPAT on plasma oxytocin levels at
the doses of 2.5 mg/kg (by 40%; p  0.05) and 5 mg/kg (by 58%;
p  0.01). For plasma ACTH in this experiment the two way
ANOVA indicated a significant main effect of 8-OH-DPAT
(F(1,54)  119.82; p  0.01), but no significant main effect of DOI
(F(3,54)  0.25; p  0.1) and no significant interaction between
DOI and 8-OH-DPAT (F(3,54)  1.47; p  0.1). However, base-
line levels of ACTH were elevated from 43.1  3.4 to 99.6  12.8.
Subtracting the baseline levels from 8-OH-DPAT-stimulated
ACTH release would indicate that the additive effects of DOI on
basal ACTH levels could have masked its desensitizing effects
(saline/DPAT group, 382.2; DOI 0.5/DPAT group, 326.6; DOI
2.5/DPAT group, 271.2; DOI 5/DPAT group, 228.4 pg/ml).
Hence the highest dose of DOI produced a 40% inhibition of
the ACTH response to 8-OH-DPAT.
Dose–response effect of 8-OH-DPAT in rats pretreated
with DOI
Increasing doses of 8-OH-DPAT (0.03, 0.05, 0.1, 0.5 mg/kg, s.c.)
or saline were administered 2 hr after DOI (2.5 mg/kg, i.p.) or
saline treatments. In saline-pretreated rats, 8-OH-DPAT signifi-
cantly increased plasma oxytocin and ACTH levels in a dose-
dependent manner. At the doses of 0.05 and 0.1 mg/kg, 8-OH-
DPAT increased plasma oxytocin to 53 and 80% of maximal
response, respectively. However, ACTH is a more amplified
hormone. At the dose of 0.05 mg/kg, 8-OH-DPAT produced a
maximal increase in plasma ACTH levels. DOI treatment shifted
Figure 1. Time course of DOI-induced reduction of the oxytocin (A) and
the ACTH (B) responses to an 8-OH-DPAT (0.05 mg/kg, s.c.) challenge.
The data represent the means  SEM of six to eight rats per group.
*Significant difference from saline/8-OH-DPAT group ( p  0.05); **sig-
nificant difference from saline/8-OH-DPAT group ( p  0.01); three-way
ANOVA and Newman–Keuls multiple range test.
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both oxytocin (Fig. 3A) and ACTH (Fig. 3B) dose–response
curves to the right, with no change in Emax. For plasma oxytocin
the two-way ANOVA showed a significant main effect of DOI
(F(1,67)  7.26; p  0.01) and a significant main effect of 8-OH-
DPAT (F(4,67)  120.00; p  0.01). The interaction between DOI
and 8-OH-DPAT was also significant (F(4,67)  3.72; p  0.01).
The Newman–Keuls test indicated that, in saline-pretreated rats,
8-OH-DPAT at the dose of 0.03 mg/kg produced no significant
effect. At the doses of 0.05 and 0.1 mg/kg, 8-OH-DPAT signifi-
cantly elevated plasma oxytocin levels. Basal plasma oxytocin
level in saline-challenged rats was not altered by DOI. However,
DOI significantly lowered the oxytocin responses to 8-OH-DPAT
at the challenge doses of 0.05 mg/kg ( p  0.05) and 0.1 mg/kg
( p  0.01), but not at the highest dose of 0.5 mg/kg (Fig. 3A). For
plasma ACTH the two-way ANOVA indicated a significant main
effect of DOI (F(1,60)  4.67; p  0.05) and a significant main
effect of 8-OH-DPAT (F(4,60)  47.7; p  0.01). There was a
significant interaction between DOI and 8-OH-DPAT (F(4,60) 
6.45; p  0.01). The Newman–Keuls test indicated that 0.03
mg/kg 8-OH-DPAT produced no significant effect on plasma
ACTH. However, a dose of 0.05 mg/kg 8-OH-DPAT already
increased plasma ACTH to its maximal level. Basal plasma
ACTH level in saline-challenged rats was not altered by DOI.
However, DOI significantly lowered the ACTH response to
8-OH-DPAT at the challenge doses of 0.05 mg/kg ( p  0.01) and
0.1 mg/kg ( p  0.05), respectively, but not at the dose of 0.5
mg/kg (Fig. 3B).
Figure 2. Examination of the doses of DOI that reduce the oxytocin (A)
and the ACTH (B) responses to an 8-OH-DPAT (0.05 mg/kg, s.c.)
challenge. The data represent the means  SEM of seven to eight rats per
group. *Significant difference from saline/8-OH-DPAT group ( p  0.05);
**significant difference from saline/8-OH-DPAT group ( p  0.01); two-
way ANOVA and Newman–Keuls multiple range test.
Figure 3. DOI shifts the oxytocin ( A) and ACTH ( B) dose–response
curve of 8-OH-DPAT effects to the right, with no change in Emax. The
data represent the means  SEM of six to eight rats per group. *Signif-
icant difference from saline/8-OH-DPAT group ( p  0.05); **significant
difference from saline/8-OH-DPAT group ( p  0.01); two-way ANOVA
and Newman–Keuls multiple range test.
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Pretreatment with the 5-HT2A antagonist MDL 100,907
prevents DOI-induced reduction of hormone
responses to 8-OH-DPAT
The basal plasma levels of oxytocin and ACTH were not altered
by MDL 100,907 or by DOI. The 8-OH-DPAT challenge signif-
icantly elevated both plasma levels of oxytocin (Fig. 4A) and
ACTH (Fig. 4B). The three-way ANOVA indicated that there
was no significant main effect of MDL 100,907 for oxytocin
(F(1,55)  2.74; p  0.1) and ACTH (F(1,55)  1.08; p  0.1). For
oxytocin there were significant interactions between MDL
100,907 and DOI (F(1,55)  7.17; p  0.01) as well as among MDL
100,907, DOI, and 8-OH-DPAT (F(1,55)  6.41; p  0.05). For
ACTH the main effect of 8-OH-DPAT was significant (F(1,55) 
109.11; p  0.01), but neither the interaction between MDL
100,907 and DOI nor the interaction among MDL 100,907, DOI,
and 8-OH-DPAT was significant. However, the Newman–Keuls
test indicated that MDL 100,907 blocked the ability of DOI to
inhibit the effect of 8-OH-DPAT on plasma levels of oxytocin
(Fig. 4A) and ACTH (Fig. 4B). Thus the effect of DOI on both
hormone responses to 8-OH-DPAT challenge is mediated pre-
dominantly by the activation of 5-HT2A receptors.
DOI does not change the level of membrane-
associated Gz-proteins in the hypothalamus
The concentration of membrane-associated Gz-proteins in the
hypothalamus of DOI- and saline-treated rats was measured by
immunoblot analysis. The specificity of the antibody for Gz-
protein has been verified in a previous study (Raap et al., 1999).
An example of an immunoblot of membrane-bound Gz-proteins
is shown in Figure 5A. The result of the densitometric analysis is
presented in Figure 5B. A Student’s t test indicates that hypotha-
lamic levels of membrane-associated Gz-proteins were not re-
duced significantly by 2.5 mg/kg DOI intraperitoneally, a dose
that significantly reduces hormone responses to an 8-OH-DPAT
challenge.
DOI does not change the GTPS-induced inhibition of
[3H]8-OH-DPAT binding in the hypothalamus
5-HT1A receptors in the hypothalamus were labeled with [
3H]8-
OH-DPAT (0.8 nM). The specific binding of [3H]8-OH-DPAT
was essentially the same when 1 M 5-HT or 1 M WAY100635
was used to define nonspecific binding. Increasing concentrations
of GTPS (from 109 to 105 M) gradually inhibited [3H]8-OH-
DPAT binding with an EC50 0.02 M and an Emax concentration
1 M (Fig. 6A).
We used 0.02 M (IC50) and 1 M (Emax) concentrations of
GTPS to examine the degree of inhibition of [3H]8-OH-DPAT
(0.8 nM) binding in the hypothalamic homogenates from saline-
and DOI-treated rats. The two-way ANOVA indicated that there
was a significant main effect of GTPS (F(42,2)  374.54; p 
0.01), but no significant main effect of DOI (F(42,1)  2.45; p 
0.1). The interaction between GTPS and DOI was not signifi-
Figure 4. The 5-HT2A receptor antagonist MDL 100,907 reverses the
inhibitory effect of DOI on the oxytocin (A) and the ACTH (B) re-
sponses to an 8-OH-DPAT (0.05 mg/kg, s.c.) challenge. The data repre-
sent the means  SEM of 7–10 rats per group. *Significant difference
from saline/8-OH-DPAT group ( p  0.01); #significant difference from
DOI/8-OH-DPAT group ( p  0.01); three-way ANOVA and Newman–
Keuls multiple range test.
Figure 5. DOI does not change the level of membrane-associated Gz-
protein in the hypothalamus. A, Immunoblot of Gz-proteins in the par-
ticulate fraction of the hypothalamic from DOI- and saline-treated rats. B,
Results of the densitometric analysis of the membrane-bound Gz-proteins
in the hypothalamus. The data represent the means  SEM of eight
hypothalamic samples per group. The data for each sample are the
average of three replicates and were analyzed with a Student’s t test.
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cant (F(42,2)  0.74; p  0.1). The Newman–Keuls test indicated
that DOI treatment did not alter the ability of both concentra-
tions of GTPS (0.02 or 1 M) to inhibit the binding of [3H]8-
OH-DPAT in hypothalamic homogenates (Fig. 6B). These data
suggest that DOI treatment does not reduce the coupling of
5-HT1A receptors to G-proteins in the hypothalamus.
DISCUSSION
The present study provides the first in vivo demonstration of a
functional heterologous desensitization of hypothalamic 5-HT1A
receptors after activation of 5-HT2A receptors. The main findings
are that (1) activation of 5-HT2A receptors with DOI produces a
delayed and transient reduction of 5-HT1A receptor-mediated
secretion of oxytocin and ACTH, with an increase in ED50 and
no change in Emax, and that (2) DOI treatment does not change
the level of membrane-associated Gz-protein or the coupling of
5-HT1A receptors to G-proteins in the hypothalamus.
8-OH-DPAT, the prototypical 5-HT1A receptor agonist, has a
high affinity for 5-HT1A receptors and from 10- to 100-fold lower
affinity for other 5-HT receptor subtypes (Hoyer et al., 1994).
The effect of 8-OH-DPAT on the secretion of ACTH and oxy-
tocin is inhibited by the 5-HT1A antagonists WAY100635, NAN-
190, and pindolol (Bagdy and Kalogeras, 1993; Critchley et al.,
1994; Meller and Bohmaker, 1994; Vicentic et al., 1998). Thus the
changes in plasma levels of ACTH and oxytocin after an 8-OH-
DPAT challenge reflect the functional state of the 5-HT1A recep-
tor system.
DOI is a 5-HT2A/2C agonist with a similar affinity for 5-HT2A
and 5-HT 2C receptors (Hoyer, 1988). Therefore, we used MDL
100,907 to determine whether 5-HT2A or 5-HT2C receptors me-
diate the DOI-induced desensitization of 5-HT1A receptors.
MDL 100,907 is a selective antagonist with 100-fold higher
affinity for 5-HT2A than for 5-HT2C receptors (Johnson et al.,
1996; Kehne et al., 1996). The dose of MDL 100,907 (0.01 mg/kg)
used in the present study was selected to avoid occupancy of
5-HT2C receptors (Dekeyne et al., 1999; Smith et al., 1999). Thus
the ability of MDL 100,907 to block the effect of DOI indicates
that 5-HT2A receptors mediate the DOI-induced desensitization
of hypothalamic 5-HT1A receptors.
Although evidence exists for receptor reserve in 5-HT1A
receptor-induced release of ACTH (Meller and Bohmaker,
1994), oxytocin is a more direct indicator of the functioning of
the hypothalamic 5-HT1A receptors after 8-OH-DPAT challenge
(Serres et al., 2000). A dose of 0.05 mg/kg 8-OH-DPAT produces
a maximal release of ACTH but only 50% of the maximal
response of oxytocin (Fig. 3). This difference in amplification may
explain our observation that DOI attenuates the oxytocin re-
sponse to 8-OH-DPAT in a dose-dependent manner (Fig. 2A),
whereas the inhibition of the ACTH response to 8-OH-DPAT is
less dramatic (Fig. 2B).
DOI increases the secretion of oxytocin and ACTH by
activating 5-HT2A receptors in the hypothalamic paraventricu-
lar nucleus (Van de Kar et al., 2001). It could be argued that a
reduction of hormone responses to a subsequent 8-OH-DPAT
challenge is attributable to a hormone-depleting effect of DOI.
However, the time course experiment indicates that, 1 hr after
treatment with DOI, there is no desensitization of the oxytocin
or ACTH responses to 8-OH-DPAT even if one would subtract
from the ACTH response the effect of DOI on baseline ACTH
levels (Fig. 1). If the pretreatment with DOI would have
depleted oxytocin, CRF, or ACTH stores, there should have
been a reduced response to 8-OH-DPAT at 1 hr after DOI
treatment. In addition, DOI pretreatment did not reduce the
maximal hormone responses to 8-OH-DPAT challenge (Fig.
3). This indicates that DOI pretreatment has not depleted
hormone stores. Thus DOI-induced attenuation of hormone
responses to the 8-OH-DPAT challenge is more likely to be
attributable to a heterologous desensitization of hypothalamic
5-HT1A receptors.
The hypothalamic paraventricular nucleus is crucial for the
serotonergic stimulation of ACTH and oxytocin release (Li-
posits et al., 1987; Saphier, 1991; Kawano et al., 1992; Bagdy
Figure 6. DOI does not change the coupling of 5-HT1A receptors to
G-proteins in the hypothalamus. A, Inhibition of [ 3H]8-OH-DPAT (0.8
nM) binding in hypothalamic homogenates with increasing concentration
of GTPS (from 10 9 to10 5 M). Each data point represents the mean of
three assays. Specific binding is defined by WAY100635 (1 M). B, DOI
does not alter the GTPS-induced inhibition of [ 3H]8-OH-DPAT binding
at the GTPS concentrations of 0.02 M (EC50 ) and 1 M (Emax ). The
data represent the means  SEM of [ 3H]8-OH-DPAT binding from eight
hypothalamic samples per group; two-way ANOVA and Newman–Keuls
multiple range test.
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and Makara, 1994; Rittenhouse et al., 1994; Van de Kar et al.,
1995). Autoradiographic studies indicate a substantial density
of [ 3H]8-OH-DPAT-labeled 5-HT1A receptors in the medial
parvocellular divisions (containing CRF neurons) and the ven-
trolateral magnocellular divisions (containing oxytocin neu-
rons) of the hypothalamic paraventricular nucleus (Li et al.,
1997). The mRNA coding for 5-HT1A receptors also has been
detected in the paraventricular nucleus (Wright et al., 1995).
Moreover, the pertussis toxin-resistant Gz-protein and Gz
mRNA are expressed in the hypothalamic paraventricular nu-
cleus (Serres et al., 2000). The 5-HT1A receptor-mediated
release of oxytocin and ACTH is not inhibited by pertussis
toxin, but it is inhibited by Gz antisense oligodeoxynucleotides
that reduce the level of Gz-protein in the paraventricular
nucleus (Serres et al., 2000). Accordingly, 8-OH-DPAT in-
creases the secretion of oxytocin and ACTH by activating
5-HT1A receptor–Gz-protein signaling systems in the hypotha-
lamic paraventricular nucleus.
Mechanical destruction of the hypothalamic paraventricular
nucleus prevents the DOI-induced increase in plasma levels of
oxytocin and ACTH (Bagdy, 1996). Autoradiographic studies
indicate the presence of 5-HT2A receptors in the hypothalamic
paraventricular nucleus (Appel et al., 1990). In addition, in situ
hybridization data indicate mRNA coding for 5-HT2A receptors
in the hypothalamic paraventricular nucleus (Wright et al., 1995;
Gundlah et al., 1999). Activation of 5-HT2A receptors with DOI
increases Fos expression in oxytocin and CRF-expressing neu-
rons, an effect that is blocked by the 5-HT2A antagonist MDL
100,907 (Van de Kar et al., 2001). Combined, it is likely that
5-HT1A receptors and 5-HT2A receptors are colocalized on CRF
and oxytocin cells, mediating oxytocin and ACTH release.
Therefore, DOI-induced desensitization of the oxytocin and
ACTH responses to a challenge with 8-OH-DPAT may represent
a heterologous desensitization of 5-HT1A receptor–Gz-protein
signaling by activation of the 5-HT2A receptors. However, there is
no evidence showing that 5-HT1A receptors or 5-HT2A receptors
are coexpressed in oxytocin or CRF cells, nor is there evidence
indicating that 5-HT1A receptors and 5-HT2A receptors are
colocalized in the same cells in the paraventricular hypotha-
lamic nucleus. Thus an alternative explanation is that DOI may
activate 5-HT2A receptors on interneurons in a complex neu-
ronal circuit, resulting in a desensitization of hypothalamic
5-HT1A receptors.
The lack of reduction in the maximal response to 8-OH-
DPAT after treatment with DOI suggests no downregulation
of 5-HT1A receptors. Consistent with this conclusion is the
observation that [3H]8-OH-DPAT binding to hypothalamic tissues
was not reduced by DOI. The time interval after DOI treatment
(2 hr) might be too short for a reduction in the density of 5-HT1A
receptors.
DOI-induced desensitization of hypothalamic 5-HT1A re-
ceptor–Gz-protein signaling is characterized by delayed onset
and short duration. These characteristics support a hypothesis
ofpost-translationalmodificationmechanismssuchasphosphory-
lation, myristoylation, or palmitoylation (Hallak et al., 1994;
Morales et al., 1998). Myristoylation and/or palmitoylation
provide anchorage for Gz-proteins to associate with the plasma
membrane and transmit extracellular signals through the
receptor down the intracellular signal transduction cascade
(Hallak et al., 1994; Beck et al., 1997). Because no change in
membrane-associated Gz-proteins was observed, it is not likely
that a change of the palmitoylation or myristoylation state of
Gz-proteins is involved in DOI-induced desensitization of
5-HT1A receptors. Phosphorylation plays an important role in
short-term receptor desensitization (Chuang et al., 1996;
Freedman and Lefkowitz, 1996). Cell culture studies demon-
strate that activation of protein kinase C induces phosphory-
lation of 5-HT1A receptors and desensitizes 5-HT1A receptor-
mediated inhibition of forskolin-stimulated cA M P
accumulation (Raymond, 1991; Evans et al., 2001). Phosphor-
ylation of Gz-proteins by protein kinase C prolongs the time
during which Gz stays in its uncoupled monomeric state
(Fields and Casey, 1995) and reduces the ability of RGSZ1
proteins to potentiate the GTPase activity of Gz-proteins
(Glick et al., 1998; Wang et al., 1998). Moreover, DOI has been
reported to increase protein kinase C activity in several brain
regions (Wang and Friedman, 1990; Rahimian and Hrdina,
1995). Therefore, it is possible that DOI activates 5-HT2A
receptors to increase the activity of protein kinase C, leading
to phosphorylation of 5-HT1A receptors and /or Gz-proteins
and to desensiti zation of 5-HT1A receptors in the
hypothalamus.
DOI treatment does not reduce the coupling of 5-HT1A recep-
tors to G-proteins in the hypothalamus. This conclusion is sup-
ported by the observation that DOI did not reduce the binding of
[ 3H]8-OH-DPAT to 5-HT1A receptors at a concentration close to
its EC50 (0.8 nM). In addition, GTPS-induced inhibition of
[ 3H]8-OH-DPAT binding to 5-HT1A receptors was not altered by
DOI. However, 5-HT1A receptors also have a high affinity for
Gi1-, Gi2-, Gi3-, and Go-proteins (Butkerait et al., 1995; Albert et
al., 1996). GTPS uncouples all Gi/o-proteins from 5-HT1A re-
ceptors with no preference for Gz. Thus it is possible that an
uncoupling of 5-HT1A receptors from Gz-proteins in the hypo-
thalamic paraventricular nucleus could be masked by a lack of
change in G-protein coupling in other hypothalamic nuclei. Sim-
ilarly, we measured only the level of membrane-associated Gz-
proteins in the whole hypothalamus and could not rule out the
possibility that DOI may alter Gz-proteins in the hypothalamic
paraventricular nucleus.
In conclusion, the activation of 5-HT2A receptors with
DOI induces a delayed onset and transient functional heterolo-
gous desensitization of 5-HT1A receptor signaling that is not
attributable to a change in the coupling of 5-HT1A receptors
to G-proteins and is not attributable to a change in the level of
membrane-associated Gz-proteins in the hypothalamus. This de-
sensitization might be attributable to changes in signaling com-
ponents distal to 5-HT1A receptor–Gz-protein interaction.
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